+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating treatments for newly diagnosed multiple myeloma in patients who cannot undergo autologous stem cell transplantation. This Phase 3 study compares two drug combinations belantamab mafodotin with lenalidomide and dexamethasone BRd versus daratumumab with lenalidomide and dexamethasone DRd. The goal is to see if BRd extends progression-free survival and improves minimal residual disease negative status compared to DRd. Participants receive either BRd or DRd treatment, continuing until disease progression, death, unacceptable side effects, withdrawal, or study end. Both treatment arms involve the administration of lenalidomide and dexamethasone alongside either belantamab mafodotin or daratumumab. Treatment duration may last up to approximately seven years. During the study, participants will undergo regular assessments including monitoring disease progression, response to treatment, and side effects. Measurements include progression-free survival, overall survival, and the number achieving minimal residual disease negative status. Quality of life questionnaires and blood tests will also be conducted. Safety monitoring includes eye exams and tracking adverse events throughout the study duration.

Age: 18Years +All GendersPhase 3
181 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
E

Actively Recruiting

Researchers are evaluating treatments for adults with multiple myeloma, a type of blood cancer that has returned or is not responding to current therapies. This Phase 2 study focuses on the drug belantamab mafodotin given less frequently alongside standard cancer medicines to see if it can effectively control the disease while reducing side effects, especially those affecting the eyes. The study also monitors overall treatment response and safety. Participants receive belantamab mafodotin combined with one of three standard regimens pomalidomide plus dexamethasone, bortezomib plus dexamethasone, or carfilzomib plus dexamethasone. The drug dosing is extended to potentially reduce side effects. The study is open-label and non-randomized, with each participant assigned to one of these three treatment combinations. During the study, participants undergo regular assessments including eye exams, tests to measure cancer response, and monitoring for side effects. The main outcome measured is the overall response rate up to about 52 months. Secondary measures include complete response rate, minimal residual disease negativity, duration of response, and detailed safety monitoring including eye-related symptoms. The study lasts until August 2030, with ongoing safety and effectiveness evaluations throughout.

Age: 18Years +All GendersPhase 2
59 locations
S

Actively Recruiting

Researchers are evaluating how well mocertatug rezetecan Mo-Rez combined with a physicians choice of immunotherapy dostarlimab or pembrolizumab works as maintenance treatment for participants with advanced or recurrent mismatch repair proficient endometrial cancer. This study compares this combination to immunotherapy alone, which is the current standard of care, and also assesses the safety, tolerability, and impact on participants quality of life. The trial is a Phase 3 randomized, open-label study sponsored by GlaxoSmithKline. Participants are assigned to one of two groups one group receives mocertatug rezetecan plus either dostarlimab or pembrolizumab, while the other group receives only the physicians choice of immunotherapy. The study treatment starts within 3 to 9 weeks after completion of first-line therapy, which includes chemotherapy and immunotherapy, and continues as maintenance therapy. The treatment duration and follow-up periods extend up to several years to monitor outcomes. During the study, participants will undergo regular assessments including scans and laboratory tests to monitor disease progression and side effects. Researchers will measure progression-free survival by blinded independent central review, overall survival, response rates, duration of response, and quality of life using specific questionnaires. Safety evaluations will include monitoring adverse events, vital signs, and laboratory parameters. The total participation time may last up to approximately 260 weeks to gather comprehensive data on treatment effects and tolerability.

Age: 18Years +FEMALEPhase 3
12 locations
R

Actively Recruiting

Researchers are evaluating mocertatug rezetecan Mo-Rez in treating endometrial cancer EC compared to standard chemotherapy options. The study aims to understand how well Mo-Rez works and how safe and tolerable it is for participants, including comparing side effects between Mo-Rez and standard treatments. This is a phase 3 randomized, open-label study focusing on treatment after prior platinum-based chemotherapy and immunotherapy. Participants will receive either mocertatug rezetecan or standard of care chemotherapy, which includes paclitaxel or doxorubicin, based on the investigators choice. The study uses a parallel design to compare these treatments directly. Treatment and assessments will continue for up to about 97 weeks for primary outcomes, with longer follow-up for secondary outcomes up to approximately 156 weeks. Throughout the study, participants will undergo multiple evaluations, including tumor response assessments by blinded independent central review and investigator assessments. Researchers will monitor progression-free survival, overall survival, treatment side effects, and quality of life using specialized questionnaires. Laboratory tests, vital signs, ECGs, and antibody measurements against the study drug will also be performed. The total participation time may extend over several years to capture long-term outcomes and safety data.

Age: 18Years +FEMALEPhase 3
56 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of a combination treatment including cevostamab, pomalidomide, and dexamethasone compared to the current standard of care in adults with multiple myeloma. Participants have previously received one to three treatments and were exposed to anti-CD38 monoclonal antibodies and lenalidomide, addressing the need for new options after prior therapies. Participants in one group will receive cevostamab intravenously on a 21-day cycle for the first cycle and then every 28 days thereafter, along with oral pomalidomide starting from the second cycle every 28 days. Dexamethasone is given as a premedication before cevostamab. The other group will receive the investigators choice of standard treatment regimens. Both treatments are monitored over an extended period to assess outcomes. Throughout the study, participants will undergo regular evaluations including disease measurements and quality of life assessments using validated questionnaires. Researchers will track responses such as complete remission and progression-free survival for up to five years after enrollment. Safety will be monitored by recording adverse events and treatment tolerability. This long-term follow-up allows comprehensive assessment of treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
93 locations
R

Actively Recruiting

Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.

All AgesAll Genders
116 locations
I

Actively Recruiting

Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.

All AgesAll Genders
54 locations